ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1766

Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients

April Barnado1, Alex Camai1 and Lee Wheless1, 1Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2020

Keywords: pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Studying pregnancy in systemic lupus erythematosus (SLE) is difficult given its relative rarity. Electronic health record (EHR) contain longitudinal data to serve as a powerful tool. Using a previously validated algorithm, we identified SLE pregnancies in a large EHR. We then examined demographics, medications, and outcomes in SLE pregnancies from 1991 to 2017.

Methods: We used a de-identified EHR with over 3 million subjects. We selected individuals using a validated algorithm of ≥ 4 counts of the SLE ICD-9 (710.0) or ICD-10 codes (M32.1*, M32.8, M32.9) and ≥ 1 ICD-9 or ICD-10 code for pregnancy-related diagnoses yielding 234 potential subjects. We extracted demographic, disease characteristics, medications, and pregnancy outcomes from chart review. SLE cases were diagnosed by a rheumatologist. We primarily analyzed only pregnancies that occurred after SLE diagnosis but then compared pregnancy outcomes before and after SLE diagnosis. SLE medication use was defined as ever use during pregnancy. In addition to a cross-sectional analysis of pregnancy outcomes, we assessed outcomes and medication use over time in 5 year increments.

Results: Of the 234 potential SLE subjects with pregnancies, there were 208 total pregnancies to definite SLE cases with 168 pregnancies occurring after SLE diagnosis and 40 pregnancies occurring before SLE diagnosis. Of 168 pregnancies that occurred after SLE diagnosis, 58% were to White women and 33% to African American women with 45% complicated by SLE nephritis and 29% antiphospholipid antibody syndrome (Table 1). Overall, SLE medication use was low with 42% of pregnancies with antimalarial use and 28% with aspirin use. Aspirin use was low over time. Antimalarial use increased over time with a peak of 62% in 2015 (Figure 1). Overall, live birth rate was 85% with 49% delivering surgically. The preterm birth rate was 42%. Preeclampsia complicated 24% of pregnancies with most occurring preterm at 82%. Mean gestational age was 35 weeks. Over time, live birth rates were similar with an increase in Caesarean section and preterm deliveries in 2005 with a subsequent decline (Figure 2). Rates for pregnancy outcome were not significantly different in pregnancies occurring before vs. after SLE diagnosis.

Conclusion: Using a large EHR, we demonstrate higher than expected rates of preterm birth and preeclampsia in SLE. These rates have not improved over time. Recommended medications in SLE pregnancy, particularly aspirin, are not dramatically increasing over time despite recommendations for use in all SLE pregnancies. These trends demonstrate the need for guideline implementation to improve SLE pregnancy outcomes.


Disclosure: A. Barnado, Nashville Biosciences, 1; A. Camai, None; L. Wheless, None.

To cite this abstract in AMA style:

Barnado A, Camai A, Wheless L. Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/trends-of-pregnancy-outcomes-in-a-large-electronic-health-record-cohort-of-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-of-pregnancy-outcomes-in-a-large-electronic-health-record-cohort-of-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology